
Natco Pharma Q2 Results 2025 Highlights: Net Profit Falls 23.46% & Revenue Down 0.59% YoY
Posted by : sachet | Mon Nov 24 2025

Click and Sign Up to Get Live Updates on Q2 Results
Natco Pharma Q2 Results FY26: During Q2 FY26, Natco Pharma’s profit decreased 23.46% YoY, while revenue decreased by 0.59% YoY. The company posted robust numbers, with Q2 PAT at ₹518.40 crores and revenue at ₹1,363.00 crores. Natco Pharma announced its Q2 results on 14th November 2025.
Natco Pharma Q2 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | |
| 30-09-2025 | 30-09-2024 | |
| Revenue from Operations | ₹1,363.00 | ₹1,371.10 |
| Profit Before Tax (PBT) | ₹679.20 | ₹868.10 |
| Profit After Tax (PAT) | ₹518.40 | ₹677.30 |
(Figures in crores)
Natco Pharma Q2 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
| Particulars | Quarter Ended | |
| 30-09-2025 | 30-09-2024 | |
| Revenue from Operations | ₹1,264.30 | ₹1,292.60 |
| Profit Before Tax (PBT) | ₹645.80 | ₹842.10 |
| Profit After Tax (PAT) | ₹500.90 | ₹661.10 |
(Figures in crores)
Natco Pharma Q2 Results FY26 Highlights (Q2 FY26 vs FY25)
- Natco Pharma clocked Q2 FY26 consolidated revenue of ₹1,363.00 crores vs ₹1,371.10 crores.
- On the profit front, Natco Pharma earned a consolidated PAT of ₹518.40 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹677.30 crore.
- According to the consolidated figures, Natco Pharma’s quarterly PAT decreased by 23.46% YoY, while revenue decreased by 0.59%.
- Natco Pharma clocked Q2 FY26 standalone revenue of ₹1,264.30 crores vs ₹1,292.60 crores.
- On the profit front, Natco Pharma earned a standalone PAT of ₹500.90 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹661.10 crore.
- According to the standalone figures, Natco Pharma’s quarterly PAT decreased by 24.23% YoY, while revenue decreased by 2.19%.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Natco Pharma Share Price Performance
On the opening bell on 24th November 2025, Natco Pharma shares opened at ₹856.00 per share. However, the initial gains have since eroded, and Natco Pharma shares are currently trading at ₹852.45 per share, lower than the opening price.
Considering the long-term performance, Natco Pharma shares have yielded returns of approximately -3.13% over the past 6 months and -37.58% over the past 1 year. Over the maximum timeframe, Natco Pharma shares delivered a return of 23,957.91% to investors.
What Analysts Expect Post Q2 Results?
Following Natco Pharma’s robust Q2 results, analysts expect its share price to rise. According to analysts, Natco Pharma’s share price is expected to reach ₹940.30 per share in the coming year; however, in a downturn, it could fall to ₹832.40 per share. However, one must ignore stock market volatility and invest in Natco Pharma’s shares after thorough research.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY
Inspira Enterprise India IPO Details: Everything You Should Know about
Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY
HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY
BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here
Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here
Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here
Related Posts
Gujarat Mineral Development Corporation Q2 Results 2025 Highlights: Net Profit Surged by 264.27% & Revenue Down 11.03% YoY
Marico Q2 Results 2025 Highlights: Net Profit Falls 0.71% & Revenue Up 30.71% YoY
Purple Wave Infocom IPO Details: Everything You Should Know about
Engineers India Q2 Results 2025 Highlights: Net Profit Falls 16.20% & Revenue Up 33.72% YoY

